Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 12-93 

Tamoxifen for 5 years vs. toremifene for 5 years with or without chemotherapy as adjuvant therapy for post/perimenopausal, node positive, hormone receptor positive breast cancer patients.

DESIGN

Design Trial 12-93

Results & Publications


Publications

Study Chairs
Dr. Olivia Pagani - Mendrisio, Switzerland
Dr. Edda Simoncini - Brescia, Italy

Statistician
Shari Gelber

Lead Trial Coordinator
Holly Shaw


Director of Data Management
Lynette Blacher

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1, 1993

Date of Closure
August 1, 1999

Targeted Accrual
960 patients

Final Accrual
452 patients


Results Publications Results & Publications
Other Pathology


News

14.11.2016:
New publications are available 

31.10.2016:
IBCSG is proud to contribute nine abstracts to the upcoming San Antonio Breast Cancer Symposium

25.10.2016:
Clinical Trials

All News

 
  Print